KIDRON NADAV 4
4 · ORAMED PHARMACEUTICALS INC. · Filed Mar 16, 2023
Insider Transaction Report
Form 4
KIDRON NADAV
DirectorPresident and CEO
Transactions
- Purchase
Common Stock
2023-03-16$2.04/sh+26,000$53,014→ 126,000 total(indirect: By wholly-owned corporation)
Holdings
- 1,053,098
Common Stock
Footnotes (1)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.02 to $2.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.